Indolent or Intermediate Grade B-cell Malignancy
1 clinical trials · Condition
◉ Watch Indolent or Intermediate Grade B-cell Malignancy
| Record | Firm | Date |
|---|---|---|
| Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies (NCT01206777) | Ohio State University Comprehensive Cancer Center | 2010-10-01 |
Track Indolent or Intermediate Grade B-cell Malignancy automatically
Every clearance here is in the API, with alerts when new ones post.